Study: Immune Enhancer Drug Zadaxin Shows Promise in Animal Tests

Laboratory animals with breast cancer that were given the immune enhancer drug Zadaxin had a four times better survival rate than a control group, according to researchers at the National Cancer Institute.

Animals with chemically-induced breast cancer were treated with either Zadaxin (thymosin alpha 1) or left untreated and were observed at weekly intervals for 21 weeks.

"These results indicate that thymosin alpha 1 delays the development of mammary carcinomas," concluded Terry W. Moody, PhD, lead researcher of the study.

"These results support numerous previously reported clinical data which indicate that Zadaxin used as a cancer therapy increases survival rates," said Dr. Alfred Rudolph, Chief Operating Officer at SciClone, makers of the drug. "We are excited about our ongoing cancer programs for Zadaxin and the potential to increase survival rates for cancer patients."

Other sources: SciClone Pharmaceuticals